Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Omeros Corp (OMER)

Omeros Corp (OMER)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Omeros: Q3 Earnings Snapshot

Omeros: Q3 Earnings Snapshot

OMER : 6.75 (-2.88%)
Omeros: Q2 Earnings Snapshot

Omeros: Q2 Earnings Snapshot

OMER : 6.75 (-2.88%)
Omeros: Q1 Earnings Snapshot

Omeros: Q1 Earnings Snapshot

OMER : 6.75 (-2.88%)
Omeros: Q4 Earnings Snapshot

Omeros: Q4 Earnings Snapshot

OMER : 6.75 (-2.88%)
Omeros: Q3 Earnings Snapshot

Omeros: Q3 Earnings Snapshot

OMER : 6.75 (-2.88%)
Omeros: Q2 Earnings Snapshot

Omeros: Q2 Earnings Snapshot

OMER : 6.75 (-2.88%)
Why Shares of Omeros Dropped on Monday

The clinical-stage biopharmaceutical released trials data through a presentation.

OMER : 6.75 (-2.88%)
Omeros: Q1 Earnings Snapshot

Omeros: Q1 Earnings Snapshot

OMER : 6.75 (-2.88%)
Omeros Corporation to Announce First Quarter Financial Results on May 9, 2023

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2023, on Tuesday, May 9, 2023, after the market closes....

OMER : 6.75 (-2.88%)
Omeros Corporation Reports Interim Data with Alternative Pathway Inhibitor OMS906 as Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria

Omeros Corporation (Nasdaq: OMER) today announced positive results from a pre-specified interim analysis of its ongoing Phase 1b clinical trial of OMS906, the company’s lead MASP-3 inhibitor, in complement-inhibitor-naïve...

OMER : 6.75 (-2.88%)

Barchart Exclusives

Skip the VIX, Buy This Dividend Stock to Profit from Volatility
Instead of trying to profit from market volatility through traditional means like the VIX, investors may want to consider buying shares of Cboe Global Markets, the company behind the VIX. Cboe Global Markets is well-positioned to benefit from rising demand for derivatives trading and offers a solid dividend yield. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar